Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.